FDA Brief

Warning letters Drugs

FDA warning letter to

Auriga Research Pvt. Ltd.

High riskIssued Aug 12Posted Aug 18Center for Drug Evaluation and Research (CDER)

Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

What happened

FDA inspected Auriga Research's contract testing laboratory in Bengaluru, India, from February 4 to 6, 2026. Investigators found incomplete raw data for microbial tests—raw test sheets had blank spaces and did not fully document plate counts—and quality unit approval of inadequate investigations into failing test results. The firm said some samples were not for the U.S. market, but FDA noted the same quality system and procedures are used for all drugs the lab tests, including U.S. drugs.

What FDA found

  1. Laboratory records for microbial tests were incomplete: raw data sheets had blank spaces and did not fully document plate counts even though summary reports listed final counts.

    21 CFR 211.194(a)
  2. The lab did not complete records at the time it performed the tests.

    21 CFR 211.194(a)
  3. The quality unit approved investigations that did not adequately establish root causes or ensure corrective and preventive actions were justified and implemented.

    21 CFR 211.22(d)
  4. For failing assay and impurity tests, the lab repeatedly retested until it got passing results and invalidated failures without scientific justification, a practice FDA called “testing into compliance.”

    21 CFR 211.22(d)
  5. The quality unit's written responsibilities and procedures were inadequate to oversee investigations and ensure drug testing quality.

    21 CFR 211.22(d)

What FDA wants

FDA tells Auriga to send a written response within 15 business days of receipt, identified with FEI 3019975128 and ATTN: Compliance Officer Barbara Wilimczyk-Macri. The response must include comprehensive assessments and remediation plans for laboratory practices, documentation and data integrity, microbial sample handling, quality unit authority and oversight, investigations, CAPA, and a three-year retrospective review of OOS results for U.S. products.

Who should pay attention

  • drug manufacturers and sponsors that use Auriga for testing
  • brands selling U.S. drug products tested by Auriga
  • quality teams relying on contract lab data for release or applications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk